AbCellera Biologics Inc. (ABCL) Stock Analysis — Probabli.AI
AI-powered analysis for ABCL (AbCellera Biologics Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $5.62 · Market cap: $1.7B · AI outlook: Bullish
AbCellera Biologics Inc. showcases significant promise as a cutting-edge player in antibody therapeutics and biologics discovery. With strong analyst consensus (STRONG BUY), ambitious revenue growth, and recent collaborations bolstering its prospects, the company is poised for substantial growth over the short and long term. Despite inherent risks tied to regulatory hurdles and market volatility,…
Probabilistic 1-Year Outlook
- Bull 65% · Neutral 25% · Bear 10%
- 1-year price estimates — P10: $5 / P50: $9 / P90: $12
- The strong analyst consensus (STRONG BUY) and impressive revenue growth estimate indicate a high likelihood of appreciation in the short term. With collaborations expanding and positive cancer therapy trial results,…
5-Year Outlook
- Bull 70% · Neutral 20% · Bear 10%
- 5-year price estimates — P10: $7 / P50: $16 / P90: $30
SWOT Highlights
- Strength: AbCellera possesses cutting-edge technology in antibody discovery.
- Strength: They benefit from growing global demand for biologics.
- Risk: High dependence on regulatory approvals.
- Risk: Potential competition within the biologics niche.
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
9 Wall Street analysts rate ABCL a STRONG BUY with a mean price target of $9.4.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
ABCL forecast details · ABCL sentiment details · ABCL insider activity
Recent saved forecast research
AI-generated research records, not evaluated investment results.
- AbCellera Biologics Inc. (ABCL) — saved
AbCellera Biologics Inc. showcases significant promise as a cutting-edge player in antibody therapeutics and biologics discovery. With strong analyst consensus (STRONG BUY), ambitious revenue growth, and recent collaborations bolstering its
- AbCellera Biologics Inc. (ABCL) — saved
AbCellera Biologics Inc. demonstrates strong growth potential due to its innovative biotech platform, robust partnership ecosystem, and trending demand for biologics. Despite regulatory scrutiny, analysts' consensus and company developments
- AbCellera Biologics Inc. (ABCL) — saved
AbCellera Biologics Inc. (ABCL) showcases strong fundamental prospects driven by exceptional revenue growth forecasts and promising technology developments. Despite current negative EPS and volatility concerns, its strategic collaborations,
- AbCellera Biologics Inc. (ABCL) — saved
AbCellera Biologics Inc. (ABCL) presents a high-growth opportunity in the biotech industry, backed by significant revenue increases, positive analyst sentiment, and collaborations with major pharmaceutical firms. The company's strong fundam
- AbCellera Biologics Inc. (ABCL) — saved
AbCellera demonstrates significant growth potential in the biotech sector. While current earnings are negative, its explosive revenue growth, innovative technology, and successful clinical developments underpinned by strong analyst support
- AbCellera Biologics Inc. (ABCL) — saved
AbCellera Biologics Inc. exhibits robust potential thanks to its leadership in AI-driven antibody discovery technology, recent strong results, and ongoing collaborations. Its technology's applications in vital therapeutic areas align with p
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.